Key Takeaways GLP-1 medications produce rapid weight loss that depletes two physical support structures simultaneously: the subcutaneous fat scaffold that provides volumetric shape, and the lean muscle beneath it that provides mechanical support
Subsequently, GLP-1s gained FDA approval for weight loss in 2014 (liraglutide: Saxenda/Victoza), 2021 (semaglutide: Wegovy/Ozempic/Rybelsus), and 2023 (tirzepatide: Zepbound/Mounjaro)
It must be combined with lifestyle changes known to promote healthy weight management, like Mediterranean-style eating and strength training
These patches aim to deliver medication continuously, maintaining steady drug levels whilst avoiding the need for weekly or daily injections
The actions of the hormone (and the medication) can help to improve blood sugar (stimulates insulin secretion), stop glucagon action (blocks stored sugar from going into the bloodstream), reduce blood sugar spikes (slows digestion/stomach emptying), and lead to eating less (promotes satiety)